Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study.

Jenny L SmithRhonda E RiesTiffany HylkemaTodd A AlonzoRobert B GerbingMarianne T SantaguidaLisa Eidenschink BrodersenLaura PardoCarrie L CummingsKeith R LoebQuy LeSuzan ImrenAmanda R LeontiAlan S GamisRichard AplencE Anders KolbJason E FarrarTimothy J TricheCu NguyenDaoud MeerzamanMichael R LokenVivian G OehlerHamid BolouriSoheil Meshinchi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

The CBFA2T3-GLIS2 fusion defines a highly refractory entity limited to infants that appears to be sufficient for malignant transformation. Transcriptome profiling elucidated several highly targetable genes and pathways, including the identification of CD56, providing a highly plausible target for therapeutic intervention.

Keyphrases

single cell
genome wide
acute myeloid leukemia
rna seq
gene expression
randomized controlled trial
bioinformatics analysis
allogeneic hematopoietic stem cell transplantation
dna methylation
young adults